<DOC>
	<DOC>NCT00755378</DOC>
	<brief_summary>This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses</brief_summary>
	<brief_title>AZD8529 Single Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Healthy male or female subjects aged 18 to 45 years (inclusive) on Day 1. Female subjects must be of nonchild bearing potential. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of the first administration of investigational prod Plasma donation within one month of screening or any blood donation/blood loss &gt; 500mL during the 3 months prior to screening Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Phase I</keyword>
</DOC>